These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12546934)

  • 1. Applications of antisense and siRNAs during preclinical drug development.
    Thompson JD
    Drug Discov Today; 2002 Sep; 7(17):912-7. PubMed ID: 12546934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotides make sensible strides.
    Doran G
    Drug Discov Today; 2004 Feb; 9(3):114-6. PubMed ID: 14960388
    [No Abstract]   [Full Text] [Related]  

  • 3. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference by mixtures of siRNAs prepared using custom oligonucleotide arrays.
    Oleinikov AV; Zhao J; Gray MD
    Nucleic Acids Res; 2005 Jun; 33(10):e92. PubMed ID: 15942024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense and siRNA technologies--SMi Conference 12-13 February 2003, London, UK.
    Gotham S
    IDrugs; 2003 Mar; 6(3):211-4. PubMed ID: 12838994
    [No Abstract]   [Full Text] [Related]  

  • 6. High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides.
    Low J; Shuguang Huang ; Dowless M; Blosser W; Vincent T; Davis S; Hodson J; Koller E; Marcusson E; Blanchard K; Stancato L
    J Biomol Screen; 2007 Sep; 12(6):775-88. PubMed ID: 17517903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense and siRNA technologies--SMi's second annual conference. 16-17 February 2003, London, UK.
    Wright P
    IDrugs; 2004 Mar; 7(3):233-4. PubMed ID: 15017464
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
    Menshykau D
    Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK.
    Cavero I
    Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway.
    Holen T; Amarzguioui M; Babaie E; Prydz H
    Nucleic Acids Res; 2003 May; 31(9):2401-7. PubMed ID: 12711685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarrays in drug discovery.
    Sauter G; Simon R; Hillan K
    Nat Rev Drug Discov; 2003 Dec; 2(12):962-72. PubMed ID: 14654795
    [No Abstract]   [Full Text] [Related]  

  • 13. RNAi and siRNA in target validation.
    Jain KK
    Drug Discov Today; 2004 Apr; 9(7):307-9. PubMed ID: 15037229
    [No Abstract]   [Full Text] [Related]  

  • 14. Positional effect of chemical modifications on short interference RNA activity in mammalian cells.
    Prakash TP; Allerson CR; Dande P; Vickers TA; Sioufi N; Jarres R; Baker BF; Swayze EE; Griffey RH; Bhat B
    J Med Chem; 2005 Jun; 48(13):4247-53. PubMed ID: 15974578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small RNAs and the regulation of cis-natural antisense transcripts in Arabidopsis.
    Jin H; Vacic V; Girke T; Lonardi S; Zhu JK
    BMC Mol Biol; 2008 Jan; 9():6. PubMed ID: 18194570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets.
    Birmingham A; Anderson EM; Reynolds A; Ilsley-Tyree D; Leake D; Fedorov Y; Baskerville S; Maksimova E; Robinson K; Karpilow J; Marshall WS; Khvorova A
    Nat Methods; 2006 Mar; 3(3):199-204. PubMed ID: 16489337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of antisense oligonucleotide and siRNA-based therapeutics.
    Chi X; Gatti P; Papoian T
    Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved early clinical development through human microdosing studies.
    Wilding IR; Bell JA
    Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808
    [No Abstract]   [Full Text] [Related]  

  • 19. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development.
    Korstanje C
    Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.